Decitabine (NSC 127716)

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR,NSC 127716

For research use only.

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Decitabine (NSC 127716) Chemical Structure

CAS No. 2353-33-5

Selleck's Decitabine (NSC 127716) has been cited by 138 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M4HTfmZ2dmO2aX;uJGF{e2G7 NUDCU4VkOC53wrFOwG0> MV6yOEBp MXr3ZZRmeg>? Mom1cY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> NFzpS209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
Eca109 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\RbXYxNjVxMj61M|Uh|ryP Mnz3NlQwPDhxN{KgbC=> NITBS5p4[XSnch?= Ml3CbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?= MlPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 NELre3dHfW6ldHnvckBCe3OjeR?= NV;3Z2ZyOC53wrFOwG0> NH7lTIM3NzF{L{K0JIg> MoK1e4F1\XJ? MkL2bY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= NUDOVGdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 M1;4e2Z2dmO2aX;uJGF{e2G7 NXjmbmdkOC53wrFOwG0> M{LLPVI1KGh? NYjhb|VLf2G2ZYK= M3;jcIlvcGmkaYTzJINmdGxiaX72ZZNqd25? NGjsfmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
Eca109 NHLtUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTaWYU3OC53wrFOwG0> M3njV|I1KGh? MYD3ZZRmeg>? MXTpcoR2[2W|IFeyM20h[XK{ZYP0JIlvKHSqZTDj[YxtKGO7Y3zl NFHUR3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
Eca109 M1rXT2Z2dmO2aX;uJGF{e2G7 MYCwMlUwOSEQvF2= MXmyOEBp NX\JfpY6f2G2ZYK= MYnk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz MmnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
SW1116  MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLUPZM5OC53L{GvNk82KM7:TR?= MnPIOFghcA>? MYrEUXNQ MXTlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u MlrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
LOVO M2rseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOwMlUwOS9{L{Wg{txO M2fXcVQ5KGh? NFP0U5hFVVOR NVrSPYQ6\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
SW1116  NVzkRYlkTnWwY4Tpc44hSXO|YYm= MYmxNEDPxE1? MXS0PEBp M{nCR2ROW09? MUjpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> M4PhdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO MVfGeY5kfGmxbjDBd5NigQ>? NFL4[FQyOCEQvF2= M13K[FQ5KGh? NF\IOFFFVVOR M1Lk[Ilv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? M{DlcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
SW1116  NE[zUHlCeG:ydH;zbZMhSXO|YYm= NW\RRpl2OTBizszN M2G4N|Q5KGh? NXPiPHd[TE2VTx?= NXTZS3Bx\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO M4LoemFxd3C2b4Ppd{BCe3OjeR?= M{nme|ExKM7:TR?= Mmr2OFghcA>? MnvJSG1UVw>? MXvlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NGrIR2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
RPMI-8226 M2PlZ2Fxd3C2b4Ppd{BCe3OjeR?= NXzodJh{OS9{IN88US=> MnfsOFgwPzJxOU[gbC=> MV7EUXNQ NEnVWW5qdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{HYc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
OPM-2  NYjXNZBmSXCxcITvd4l{KEG|c3H5 M{DmRlEwOiEQvF2= MVu3Nk86Pi9zMkCgbC=> MXTEUXNQ MYfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYjkPHFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
JJN3  NUjmPHJvSXCxcITvd4l{KEG|c3H5 NW\tNINJOC53L{Gg{txO NGHVPI0zPC92ODDo Mk[1SG1UVw>? MWnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4jw[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
NCI-H929  NFP6RVlCeG:ydH;zbZMhSXO|YYm= NFrPVlcyNzJizszN NHzJeGE4Oi97Nj:xNlAhcA>? NX36UWtRTE2VTx?= MUDpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4fhZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
RPMI-8226 NG\NOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rKNVEwOiEQvF2= NV7TNFY{OjRxNEivO|IhcA>? NU[wT3VzTE2VTx?= MorCZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NILFXJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
OPM-2  MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DBc|EwOiEQvF2= Mk\UNlQwPDhxN{KgbC=> M1PhSmROW09? Mk\0ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
JJN3  MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXiVIgxNjVxMTFOwG0> M4TTelI1NzR6L{eyJIg> NXXtSIZjTE2VTx?= MXnh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? M3HYfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
NCI-H929  NFr4RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuwU3kyNzJizszN NWDLVHJQOjRxNEivO|IhcA>? MV;EUXNQ NXfCeWtz[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
HeLa M{TqT2tqdmG|ZTDBd5NigQ>? M1nFeWtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> NYHlVZlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
HeLa NF[4O5ZMcW6jc3WgRZN{[Xl? NHH2fFBMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> NXHEfW1JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
HeLa MoHCT4lv[XOnIFHzd4F6 NHnUfHNMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy M3\USlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
HeLa M1r0emtqdmG|ZTDBd5NigQ>? NX\t[pZzU2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>? NVywR3d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
NB4 M3\kXWZ2dmO2aX;uJGF{e2G7 MVSyMlUwPS95LkWvNVAh|ryP MV6yOEBp M{jZdmROW09? M13Rb4lv[3KnYYPlZUB1cGViZYjwdoV{e2mxbjDv[kBxemWldYLzc5IhdWmULUGyOYE> M1PyclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEi0PFcxLz5{NES4OFg4ODxxYU6=
CD4+ CD25− T  M4HnWWZ2dmO2aX;uJGF{e2G7 NVT2eHBpOS93IN88US=> Mm\ydoVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v Mn3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{[zOlAoRjJ2NEe2N|YxRC:jPh?=
BV-173 M2HDcGFxd3C2b4Ppd{BCe3OjeR?= NVPYeoJ5OC5{NT:wMlUwOC55NT:xJO69VQ>? M2T3RVQ5Nzd{L{m2JIg> MVdCpHBDWw>? MlLxbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NYPsbFJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
ML-1 NHTnTJlCeG:ydH;zbZMhSXO|YYm= NUnO[lc6OC5{NT:wMlUwOC55NT:xJO69VQ>? MmfPOFgwPzJxOU[gbC=> NXeyNYZGyqCSQmO= NHG3U5pqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MoOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
HL-60 MXTBdI9xfG:|aYOgRZN{[Xl? M1vVcVAvOjVxMD61M|AvPzVxMTFOwG0> NGPtdWU1QC95Mj:5OkBp M3rTSeKhWEKV NF[wU|lqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
KG-1a MofURZBweHSxc3nzJGF{e2G7 MV2wMlI2NzBwNT:wMlc2NzFizszN MYG0PE84Oi97NjDo Mn3sxsBRSlN? M17TSIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
BV-173 MU\GeY5kfGmxbjDBd5NigQ>? NGrkfHQzPTBxNUCwcm0> M3viZ|Q5KGh? MlLhxsBRSlN? NIG1WYRqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M3O1PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
CEM NXrrOYY2TnWwY4Tpc44hSXO|YYm= NFfYd5YzPTBxNUCwcm0> M3myTFQ5KGh? MYZCpHBDWw>? MoXkbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60 M1mxU2Z2dmO2aX;uJGF{e2G7 MlS1NlUxNzVyMH7N NYfHZYRpPDhiaB?= M33hfuKhWEKV NXj2WZVncW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl M2jFNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
ML-1 NHv6eXRHfW6ldHnvckBCe3OjeR?= NXPtPY56OjVyL{WwNI5O NETjT2c1QCCq NYLlbYx[yqCSQmO= M4HmfYlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MmDwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MkO2NVMoRjJ2NEKzOlE{RC:jPh?=
DLD-1 NVfOUG1STnWwY4Tpc44hSXO|YYm= MoPnNlUxNzVyMH7N M3HlOVQ5KGh? M1LZSOKhWEKV NYPZ[lBx\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HCT-116 MkX0SpVv[3Srb36gRZN{[Xl? MUiyOVAwPTBybl2= NVXndVNTPDhiaB?= NUnhWGE3yqCSQmO= MnXt[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? NFXFc3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
U937-A/E-9/14/18  M2POZmFxd3C2b4Ppd{BCe3OjeR?= NUThSGpzOC5yMT:wMlEwOS9zMDFOwG0> MkjnOFghcA>? NX3LTJhZcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXzqS2V3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNFA1PTZpPkK0N|AxPDV4PD;hQi=>
HT29 NV[2WHlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOyc2QxPzJiaB?= MWPJR|UxRTF2MEFCtVE4QSEQvF2= NXHXVY5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO|IxPjFpPkK0NVczODZzPD;hQi=>
SW48 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\5O|IhcA>? MnjFTWM2OD1zNT6yxtE3NjJizszN NEnaNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NlA3OSd-MkSxO|IxPjF:L3G+
HCT116 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrxXHhCPzJiaB?= NFjRTm1KSzVyPUGuO:KyOC52IN88US=> M4PYcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUeyNFYyLz5{NEG3NlA3OTxxYU6=
HepG2 MUTGeY5kfGmxbjDBd5NigQ>? NUnkNnpUOC53L{Gg{txO MY[yOEBp MWjEUXNQ M{Th[JVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NWnxflFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
LS174T MXXGeY5kfGmxbjDBd5NigQ>? MoO4NE42NzFizszN NXftTpc6OjRiaB?= NX3DeGhtTE2VTx?= NWGxZogxdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
HepG2 NH\WR5VCeG:ydH;zbZMhSXO|YYm= NInIO2syNzFyL{GwNEDPxE1? NGPUR2k4KGR? M4fzUGROW09? MoXobY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
LS174T NH7CV2hCeG:ydH;zbZMhSXO|YYm= NYP5O4RMOS9zMD:xNFAh|ryP NHTydXM4KGR? NFXPNHNFVVOR NXPOTldvcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXvvXnlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
QBC-939 M2ixN2Fxd3C2b4Ppd{BCe3OjeR?= MWixM|ExNzFyMDFOwG0> NF\WV4s4KGR? NGHhe|NFVVOR M{TsZYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUDITFM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
U251 MnTNRZBweHSxc3nzJGF{e2G7 MV2xM|ExNzFyMDFOwG0> MmPzO{Bl M1q4NmROW09? NIj5R|FqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{nnbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
HL-60 MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m2XlEh|ryP MlHrOFghcA>? M2HMc4lv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w NU\ZfGtyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNFA{OjRpPkK0NFAxOzJ2PD;hQi=>
MDA‑MB‑453 MmXLSpVv[3Srb36gRZN{[Xl? NFHiZYQxNjJxMTFOwG0> NVLnS|FLPzJiaB?= NFH0[2lk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MmrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESyNlgoRjJ|OES0NlI5RC:jPh?=
HCC1569 NV\TXnU4TnWwY4Tpc44hSXO|YYm= MmrBNE4zNzFizszN NHXmW444OiCq NH\aVoFk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NW\LZ5Q5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQzOjhpPkKzPFQ1OjJ6PD;hQi=>
BT‑474 MYXGeY5kfGmxbjDBd5NigQ>? NIjwcVkxNjJxMTFOwG0> NYTuS4ZDPzJiaB?= NFqze2Vk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> M2Xib|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
AGS M3riXWFxd3C2b4Ppd{BCe3OjeR?= NG\6UmY2NzFyL{KwM|UxKM7:TR?= MWe0POKhcMLi NYXuVHZuTE2VTx?= NEOzPIlqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NV3INlRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PFI4QDRpPkKzOVgzPzh2PD;hQi=>
A549 M2XpNmFxd3C2b4Ppd{BCe3OjeR?= MnTUOU8yOC9{MD:1NEDPxE1? MoT2OFjDqGkEoB?= MnPISG1UVw>? MWTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> M{D5SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
AGS  M4fMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[1M|ExNzJyL{WwJO69VQ>? MmDpOFjDqGkEoB?= M33OcGROW09? MnHqbY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg MnXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ|NUiyO|g1RC:jPh?=
Kasumi-1 M3HGSWFxd3C2b4Ppd{BCe3OjeR?= M2fGXlAvPSEQvF2= MnfoOFjDqGkEoB?= NWPyXHox\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MnjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ|NEmzN|Q5RC:jPh?=
OCI-AML3 NVXDcYZLSXCxcITvd4l{KEG|c3H5 NHfifFMzNjVizszN NHH3N4o1QMLiaNMg MV7k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= M3:0XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEmzN|Q5Lz5{M{S5N|M1QDxxYU6=
MV4-11 MV7BdI9xfG:|aYOgRZN{[Xl? M2jSZVIvPSEQvF2= M1:4WVQ5yqCqwrC= MU\k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NUTaV5ViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM{PDhpPkKzOFk{OzR6PD;hQi=>
NK  MkjSR5l1d3SxeHn0fUBCe3OjeR?= MVywMlAzNTJyIN88US=> MX21JIQ> NX7vUGZw\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?= NYq2SnpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNlgxQDhpPkKzN|I5ODh6PD;hQi=>
NK  NXPzVI43SXCxcITvd4l{KEG|c3H5 NGXWOnYxNjB{LUKwJO69VQ>? NFSzUGE2KGR? NIL2cW9l\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? Mk\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MkiwPFgoRjJ|M{K4NFg5RC:jPh?=
NK  M2nmNGZ2dmO2aX;uJGF{e2G7 MlzFNE4xOS1{MDFOwG0> M3zSOlUh\A>? M3\ZcINifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEC4PEc,OjN|MkiwPFg9N2F-
MOLT4/DNR MkPKSpVv[3Srb36gRZN{[Xl? M2Xnb|Uh|ryP MknROEBl MorVdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NWHUe|BmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwOlA2PzBpPkKzNFYxPTdyPD;hQi=>
Jurkat/DOX M1jvfGZ2dmO2aX;uJGF{e2G7 MlfWOUDPxE1? NVLmS3k5PCCm NYqxfXJ5emWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MEW3NEc,OjNyNkC1O|A9N2F-
MOLT4/DNR M{LhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\pOUDPxE1? NFvsOHU1KGR? MlixdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NIrVR2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2NFU4OCd-MkOwOlA2PzB:L3G+
Jurkat/DOX NYDvSHZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXaOUDPxE1? MUe0JIQ> NWjqfnk5emWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MEW3NEc,OjNyNkC1O|A9N2F-
ccRCC  MkPkRZBweHSxc3nzJGF{e2G7 NFHpbYMxNjBzLUGw{txO MkDkO|IhcA>? MlPqSG1UVw>? MoDUbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MoDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Mk[0OlcoRjJ{OEK2OFY4RC:jPh?=
TNBC  Mn7rRZBweHSxc3nzJGF{e2G7 NHW0XHUxNjBzLUGw{txO MlrsO|IhcA>? NIXB[VRFVVOR NInZPZRp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
A498 NF;1NXdCeG:ydH;zbZMhSXO|YYm= NWe2VIpXOC5yMT2xNO69VQ>? NVXMVZJqPzJiaB?= NVWwTI9bTE2VTx?= NVvxUmZXcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
KIJ265T Ml3GRZBweHSxc3nzJGF{e2G7 MlvhNE4xOS1zMN88US=> NUP3NVhvPzJiaB?= NX7KNmF6TE2VTx?= NVHlPY13cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? Ml;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Mk[0OlcoRjJ{OEK2OFY4RC:jPh?=
MDA-231 NEWzUWlCeG:ydH;zbZMhSXO|YYm= MVmwMlAyNTFyzszN MmP1O|IhcA>? MkjMSG1UVw>? MnfBbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NUDLN4dXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
BT-20 NF;YVm9CeG:ydH;zbZMhSXO|YYm= M1viOFAvODFvMUFOwG0> MmizO|IhcA>? MXHEUXNQ NGi0S2NqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NWXlcnN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
U937 NVe0NnZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\QOU0zOCEQvF2= M1;DdFI1NzR6L{eyJIg> MVrpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M4DB[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O|AzOTxxYU6=
HL60 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjxTY82NTJyIN88US=> NEm3S|QzPC92OD:3NkBp NX\H[HVOcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? Mk\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5NkewNlEoRjJ{N{[3NFIyRC:jPh?=
U937 MlXpRZBweHSxc3nzJGF{e2G7 MnmxNVUh|ryP MWeyOE81QC95MjDo NHuzPW1qdmS3Y3XzJINmdGxiYYDvdJRwe2m| MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60 Mn\CRZBweHSxc3nzJGF{e2G7 NH31R|cyPSEQvF2= NIPLS3EzPC92OD:3NkBp NV\XNIxMcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NXjFTnlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO|Y4ODJzPD;hQi=>
LS411N  MXTBdI9xfG:|aYOgRZN{[Xl? Mn7SNE42KM7:TR?= MYS3NkBp M2LMWIlv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR4MU[5OUc,OjJ2NkG2PVU9N2F-
MDA-MB-231 NIruUJVCeG:ydH;zbZMhSXO|YYm= NVHXPIJ7OTBizszN MWS0PEBp MXLy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEjWTIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi4O|Y6Pyd-MkG4PFc3QTd:L3G+
MCF-7  MlPmRZBweHSxc3nzJGF{e2G7 MWixNEDPxE1? M3;CSFQ5KGh? NFP0[HVz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3K0NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEi3Olk4Lz5{MUi4O|Y6PzxxYU6=
A375 NYXMOIZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHBSGoxNjVizszN Mk\aNU82NzhiZB?= Mli1bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrCfoExNjVizszN M1;JelEwPS96IHS= NInjeIJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NXXWRlRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO|k3PjJ{PD;hQi=>
SKMEL3 M{S0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWwMlUh|ryP NX7K[m1TOS93L{ig[C=> M3mzPYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL28 NVu2fHRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHaNE42KM7:TR?= MXuxM|UwQCCm M2jKPYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
MeWo NWfEV4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TBeFAvPSEQvF2= NInnOpMyNzVxODDk NXPmNVFJcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
B16 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKwMlUh|ryP M{OxTFEwPS96IHS= NInUNoVqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MlzsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
Ly 1 M3jBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37lXVI1KGh? MlvDTWM2OD15LkOg{txO NHWy[4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 7 NULEZ2huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2qzOFI1KGh? MUnJR|UxRTFyLkeg{txO MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6 NInSelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrFZY0zPCCq MYTJR|Ux97zgMkCg{txO MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 10 M176TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XrclI1KGh? Mm\nTWM2OO,:nkKwJO69VQ>? M2\qTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\zT3YzPCCq MVLJR|Ux97zgMkCg{txO NIPaPW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL2 NHKyc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjxZ5AzOjRiaB?= Mk\YTWM2OO,:nkKwJO69VQ>? NIPP[FE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 1 M2PqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\POFghcA>? MYXJR|UxRTBwM{Sg{txO MnTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 7 M1m0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjT[ZFtPDhiaB?= MYnJR|UxRTBwMEK1JO69VQ>? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6 MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfRNHE1QCCq M{nFR2lEPTExvK6yNEDPxE1? M17Ge|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10 NXvaNJZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v0N|Q5KGh? MWrJR|UxRTFwODFOwG0> M3jUWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA NVuyPWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP2fZdUPDhiaB?= NEPJZ4JKSzVy78{eNlAh|ryP MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2 M2PvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTLXXpkPDhiaB?= NYT5flZOUUN3ME2xO{41KM7:TR?= NHTXS409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvaO|IhcA>? MlrSTWM2OD1yLkCxJO69VQ>? Mo[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfxTow4OiCq NITDSmxKSzVyPUCuNFE5KM7:TR?= NHTIRlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL6 M{TUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTT[mY4OiCq NIfiRZJKSzVyPUGuOkDPxE1? NUTDZ5JpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 10 NXXrSmlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV62e3J7PzJiaB?= NGr4c5hKSzVyPUGuNkDPxE1? M2TjdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA NVTVb2kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3qW5UxPzJiaB?= MkT4TWM2OO,:nkKwJO69VQ>? NF3heZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL2 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzxeZBpPzJiaB?= NHHmNIVKSzVyPUGxMlIh|ryP NHfBT2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
U373-MAGI MnzERY51cX[rcnHsJIF{e2G7 MkHpNE4zPSC2bzC4JJVO NFy0Z48zKHSxIEeyJIhzew>? MmTYRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWnNXNUdicIPleYRwfHmyZXSgTGlXNTFiTly0MVMhcW6oZXP0[YQhcW5iaIXtZY4hXTN5Mz3NRWdKKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDVOU1o[WdibHX2[Ywh[XRiMD6yOUB1dyB6IIXNJIFnfGW{IEKgeI8hPzJiaILzJIJ6KHGSQ2KgcYV1cG:m MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{K2NEc,OjdzMUeyOlA9N2F-
U373-MAGI NFO5fIhCdnSrdnnyZYwh[XO|YYm= MlnTNE4zPSC2bzC4JJVO M{jkbVIhfG9iN{KgbJJ{ M{naWmFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6g[4FoKGyndnXsJIF1KDBwMkWgeI8hQCC3TTDh[pRmeiB{IITvJFczKGi{czDifUByWEOUIH3leIhw\A>? NVzvR4RTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVczPjBpPkK3NVE4OjZyPD;hQi=>
Assay
Methods Test Index PMID
Western blot Survivin / Bcl-2 / p53 / c-Myc / DNMT1 ; p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN ; phospho-p38 / p38 / phospho-NFκB / NFκB ; p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax 26384351 25762617 26617834 26692933 28152502
Immunofluorescence DNMT1 ; E-cadherin / MMP-9 21303982 28152502
Growth inhibition assay Cell viability 26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol (from reference)

Kinase Assay:[1]
  • DNA synthesis assay :

    The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.

Cell Research:[1]
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
Animal Research:[2]
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.

10mg/mL

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05360160 Not yet recruiting Drug: SNDX-5613|Drug: Venetoclax|Drug: ASTX727 Acute Myeloid Leukemia M.D. Anderson Cancer Center|Astex Pharmaceuticals Inc.|Syndax Pharmaceuticals Inc. October 31 2022 Phase 1|Phase 2
NCT05403450 Recruiting Drug: Tolinapant|Drug: Decitabine + Cedazuridine Relapsed/Refractory Peripheral T-cell Lymphoma Astex Pharmaceuticals Inc. June 23 2022 Phase 1|Phase 2
NCT04985656 Withdrawn Drug: Pevonedistat|Drug: Decitabine|Drug: Cedazuridine Myelodysplastic Syndromes (MDS) Takeda October 1 2021 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?

Answer:
S1200 is R form

Tags: buy Decitabine (NSC 127716) | Decitabine (NSC 127716) supplier | purchase Decitabine (NSC 127716) | Decitabine (NSC 127716) cost | Decitabine (NSC 127716) manufacturer | order Decitabine (NSC 127716) | Decitabine (NSC 127716) distributor